OrSense Announces the Appointment of Mr. Carlo Salvi to its Board of Directors

Company Completes U.S. $ 6 Million Private Financing

Nes Ziyyona, Israel, February 6, 2006 - OrSense Ltd., a developer of non-invasive glucose monitoring products, announced today that Mr. Carlo Salvi, a Director at Teva Pharmaceuticals (Nasdaq: TEVA), has been appointed to its Board of Directors, effective immediately. The Company also announced today that several investors have committed an additional U.S. $6.0 million in funding to the Company. The investment was led by Israel Healthcare Ventures (IHCV). Other investors include STAR Ventures and Lewis Trust
Group (LTG).

OrSense is a medical device company positioned to bring the world's first non-invasive glucose monitoring products to the market. The Company's products are based on its proprietary Occlusion Spectroscopy technology, which overcomes key obstacles that hinder the performance of competing approaches. Additional OrSense products focus on non-invasive monitoring of other critical blood parameters, such as hemoglobin. OrSense's products will significantly reduce the need for needle-stick blood tests, and address markets of over U.S.$8 billion annually.

"I am delighted to welcome Carlo as a director of the Company. Carlo brings to OrSense extensive experience and industry knowledge, and I look forward to working with him," said Shimon Eckhouse, Ph.D., Chairman of OrSense's Board of Directors. "We believe that this additional investment will help us establish OrSense as the world leader in non-invasive glucose monitoring, promising a significant improvement to the quality of life of people with diabetes," added Dr. Eckhouse.

"I am excited by the prospect of working with OrSense as a director and an advisor. I have also decided to increase my investment in the Company through IHCV, because I believe that their unique non-invasive monitoring systems address major unmet medical needs and represent a potential for rapid market acceptance and profitability," stated Mr. Carlo Salvi.

Mr. Carlo Salvi has extensive executive experience in the healthcare industry and currently also serves on the Board of Directors of Teva Pharmaceuticals. Mr. Salvi joined Teva's Board in January 2004, upon completion of the acquisition of Sicor by Teva. Previously, Mr. Salvi served in various senior managerial positions at Sicor including Vice Chairman, President and CEO, and Director and was Chairman of the Board of Sicor S.p.A.

About OrSense
OrSense is a medical device company developing non-invasive glucose monitoring systems for people with diabetes. The Company's products are based on its proprietary Occlusion Spectroscopy technology. OrSense also develops and markets non-invasive monitoring products for other critical blood parameters, such as hemoglobin. The Company's first commercial product is CE approved for monitoring hemoglobin and hematocrit. OrSense's intellectual property portfolio consists of 18 granted patents, with over 25 additional applications in process. Investors include Israel Health Care Ventures and STAR Ventures. For additional information, please visit OrSense's corporate Website at www.orsense.com.

Press Contact:
Tsipi Haitovsky
Media Liaison
OrSense Ltd.
Tel: +972-52-598-9892
Email: tsipi.haitovsky@orsense.com